Adjust to target in type 2 diabetes: comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine

Richard M Bergenstal, Mary Johnson, Margaret A Powers, Alan Wynne, Aleksandra Vlajnic, Priscilla Hollander, Marc Rendell, Richard M Bergenstal, Mary Johnson, Margaret A Powers, Alan Wynne, Aleksandra Vlajnic, Priscilla Hollander, Marc Rendell

Abstract

Objective: Carbohydrate counting is an effective approach to mealtime insulin adjustment in type 1 diabetes but has not been rigorously assessed in type 2 diabetes. We sought to compare an insulin-to-carbohydrate ratio with a simple algorithm for adjusting the dose of prandial insulin glusiline.

Research and design methods: This 24-week, multicenter, randomized, controlled study compared two algorithms for adjusting mealtime (glulisine) insulin along with a standard algorithm for adjusting background (glargine) insulin in 273 intent-to-treat patients with type 2 diabetes. Glulisine and glargine were adjusted weekly in both groups based on self-monitored blood glucose (SMBG) results from the previous week. The simple algorithm group was provided set doses of glulisine to take before each meal. The carbohydrate counting (carb count) group was provided an insulin-to-carbohydrate ratio to use for each meal and adjusted their glulisine dose based on the amount of carbohydrate consumed.

Results: A1C levels at week 24 were 6.70% (simple algorithm) and 6.54% (carb count). The respective mean A1C changes from baseline to 24 weeks were -1.46 and -1.59% (P = 0.24). A1C <7.0% was achieved by 73.2% (simple algorithm) and 69.2% (carb count) (P = 0.70) of subjects; respective values for A1C <6.5% were 44.3 and 49.5% (P = 0.28). The total daily dose of insulin was lower, and there was a trend toward less weight gain in carb count group patients. Severe hypoglycemia rates were low and equal in the two groups.

Conclusions: Weekly basal-bolus insulin adjustments based on premeal and bedtime glucose patterns resulted in significant reductions in A1C. Having two effective approaches to delivering and adjusting rapid-acting mealtime insulin may increase physicians' and patients' willingness to advance therapy to a basal-bolus insulin regimen.

Trial registration: ClinicalTrials.gov NCT00135057.

Figures

Figure 1—
Figure 1—
Disposition of patients. AEs, adverse events.
Figure 2—
Figure 2—
A: A1C: change from baseline in simple algorithm and carb count groups at weeks 2, 6, 12, 18, and 24 (ITT population). B: FPG: change from baseline in simple algorithm and carb count groups at weeks 2, 6, 12, 18, and 24 (ITT population). C: Glucose profiles from 7-point SMBG testing at baseline and week 24 in simple algorithm and carb count groups (ITT population).

References

    1. Home P: Contributions of basal and post-prandial hyperglycaemia to micro- and macrovascular complications in people with type 2 diabetes. Curr Med Res Opin 21:989–998, 2005
    1. Heine RJ, Balkau B, Ceriello A, Del Prato S, Horton ES, Taskinen M-R: What does postprandial hyperglycaemia mean? Diabet Med 21:208–213, 2004
    1. Ceriello A: Postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes 54:1–7, 2005
    1. Wright A, Burden AC, Paisey RB, Cull CA, Holman RR, UK Prospective Diabetes Study Group: Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK Prospective Diabetes Study (UKPDS 57). Diabetes Care 25:330–336, 2002
    1. Gerich JE: Novel insulins: expanding options in diabetes management. Am J Med 113:308–316, 2002
    1. Dreyer M, Prager R, Robinson A, Busch K, Ellis G, Souhami E, Van Leendert R: Efficacy and safety of insulin glulisine in patients with type 1 diabetes. Horm Metab Res 37:702–707, 2005
    1. Gross TM, Kayne D, King A, Rother C, Juth S: A bolus calculator is an effective means of controlling postprandial glycemia in patients on insulin pump therapy. Diabetes Technol Ther 5:365–369, 2003
    1. Kalergis M, Pacaud D, Strychar I, Meltzer S, Jones PJ, Yale JF: Optimizing insulin delivery: assessment of three strategies in intensive diabetes management. Diabetes Obes Metab 2:299–305, 2000
    1. DAFNE Study Group: Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial. BMJ 325:746–751, 2002
    1. Peragallo-Dittko V (Ed.): A Core Curriculum for Diabetes Education. 4th ed. Chicago, American Association of Diabetes Educators, 2001
    1. Kaufman FR, Halvorson M, Carpenter S: Use of a plastic insulin dosage guide to correct blood glucose levels out of the target range and for carbohydrate counting in subjects with type 1 diabetes. Diabetes Care 22:1252–1257, 1999
    1. Rickheim P, Flader J, Carstensen KM: Type 2 Diabetes BASICS. 2nd ed. Minneapolis, International Diabetes Center, 2004
    1. American Association of Clinical Endocrinologists/American College of Endocrinology: The American Association of Clinical Endocrinologists medical guidelines for the management of diabetes mellitus: the AACE system of intensive diabetes self-management—2002 update. Endocr Pract 8:41–82, 2002
    1. American Diabetes Association: Standards of medical care in diabetes. Diabetes Care 29(Suppl. 1):S4–S42, 2006
    1. Raskin P, Klaff L, Bergenstal R, Halle JP, Donley D, Mecca T: A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care 23:1666–1671, 2000
    1. De Leeuw I, Vague P, Selam JL, Skeie S, Lang H, Draeer E, Elte JWF: Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes Metab 7:73–82, 2005
    1. Holman RR, Thorne KI, Farmer AJ, Davies MJ, Keenan JF, Paul S, Levy JC, 4-T Study Group: Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 1716–1730, 2007
    1. Garg SK, Rosenstock J, Ways K: Optimized basal-bolus insulin regimens in type 1 diabetes: insulin glulisine versus regular human insulin in combination with basal insulin glargine. Endocr Pract 11:11–17, 2005
    1. Dailey G, Rosenstock J, Moses RG, Ways K: Insulin glulisine provides improved glycemic control in patients with type 2 diabetes. Diabetes Care 27:2363–2368, 2004
    1. Rosenstock J, Ahmann AJ, Colon G, Scism-Bacon J, Jiang H, Martin S: Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents. Diabetes Care 31:20–25, 2008
    1. Reichard P, Nilsson BY, Rosenqvist U: The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 329:304–309, 1993
    1. Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of the long-term complications of insulin-dependent diabetes mellitus. N Engl J Med 329:977–986, 1993
    1. Ohkubo Y, Kishikawa H, Araki E, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 28:103–117, 1995
    1. UK Prospective Diabetes Study Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853, 1998
    1. Buse JB: Should postprandial glucose be routinely measured and treated to a particular target? No! Diabetes Care 26:1615–1618, 2003

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel